Abramson D H, Gamell L S, Ellsworth R M, Kruger E F, Servodidio C A, Turner L, Sussman D
Ophthalmic Oncology Center, New York Hospital--Cornell Medical Center, New York.
Br J Ophthalmol. 1994 Sep;78(9):698-701. doi: 10.1136/bjo.78.9.698.
A retrospective chart review of 427 eyes diagnosed with unilateral retinoblastoma was performed to determine which eyes, which patients, and when new intraocular tumours would develop after treatment. Mean follow up was 8.16 years. Twenty five (6%) of 427 unilateral retinoblastoma patients developed new intraocular tumours after treatment. Five (1%) unilateral patients who were previously treated with enucleation developed new tumours (in the fellow eye). Fifteen (24%) unilateral patients who were previously treated with external beam radiation developed new tumours (equally in either eye). New tumours did not develop in the macula of either eye. The relative risk of developing new intraocular tumours after treatment was 16% in patients diagnosed before 1 year old and 2.2% for patients diagnosed after 1 year old (p < 0.001). The mean time to onset for the development of new tumours after treatment was 0.74 years; no new tumours appeared after 7.5 years of age. Those patients who are diagnosed with unilateral retinoblastoma in the first 6 months of life and have a family history of the disease are at greatest risk of developing new intraocular tumours.
对427例诊断为单侧视网膜母细胞瘤的患者进行了回顾性病历审查，以确定哪些眼睛、哪些患者以及治疗后何时会出现新的眼内肿瘤。平均随访时间为8.16年。427例单侧视网膜母细胞瘤患者中有25例（6%）在治疗后出现了新的眼内肿瘤。5例（1%）先前接受眼球摘除术的单侧患者出现了新肿瘤（在对侧眼）。15例（24%）先前接受外照射放疗的单侧患者出现了新肿瘤（两眼出现的概率相同）。两眼的黄斑区均未出现新肿瘤。1岁前确诊的患者治疗后发生新眼内肿瘤的相对风险为16%，1岁后确诊的患者为2.2%（p<0.001）。治疗后新肿瘤出现的平均时间为0.74年；7.5岁后未出现新肿瘤。那些在出生后前6个月被诊断为单侧视网膜母细胞瘤且有家族病史的患者发生新眼内肿瘤的风险最大。
